Gene Targeting Attention to Detail by Vanhaesebroeck, Bart et al.
Cell
274
tylate Pael-R, but also because it leads to dissociation Gene targeting in mice is a powerful tool for uncovering
the physiological roles of proteins and is increasinglyof Hsp70 from Parkin and Pael-R, thus further driving
being used for preclinical validation of potential newPael-R degradation (Imai et al., 2002). It will be interest-
drug targets (Harris, 2001). Different experimental strate-ing to determine whether the UFD-2/CHN-1 complex
gies of gene targeting can, however, give rise to verymay similarly lead to dissociation of Hsp90 from UNC-
distinct phenotypes. The commonest pitfalls include45, something that could contribute to rendering it more
“neighborhood” phenotypic effects caused by retentionprone to degradation. UNC-45 proteins are conserved
of selection cassettes in the targeted locus, multipleacross metazoan evolution (Hutagalung et al., 2002) and
gene inactivation, and creation of truncated biologicallyUFD2, as well as CHIP, are abundantly expressed in
active gene products, any of which can lead to “off-human muscle cells (Ballinger et al., 1999; Mahoney et
target” phenotypes. It is also becoming increasinglyal., 2002). Therefore, the regulation of myosin assembly
clear that “knocking out” (KO) a gene is not the equiva-via multiubiquitylation of UNC-45 uncovered in C. ele-
lent of “knocking in” (KI) an inactivating point mutationgans should have important implication for understand-
or an otherwise disabled full-length version of the gene.ing myosin assembly during physiological and patholog-
A prime example highlighting how different gene inacti-ical conditions in humans. Moreover, since other UCS
vation strategies can lead to strikingly different pheno-proteins interact with unconventional myosin, increased
types is published in this issue of Cell (Patrucco et al.,understanding of the mechanisms by which multiubiqui-
2004). In this study, Hirsch’s group inactivated p110,tylation regulates their function will undoubtedly shed
a member of the phosphoinositide 3-kinase (PI3K) genelight on other myosin-dependent processes such as cell
family, by knocking in a kinase-dead version into themotility and cytokinesis.
endogenous p110 gene locus, and observed a very
unexpected result.
PI3Ks generate lipid signals downstream of receptorsPierre Go¨nczy
and are considered to be good targets for pharmacologi-ISREC (Swiss Institute for Experimental Cancer
cal intervention in diseases associated with deregulatedResearch)
PI3K activity, such as cancer, inflammation, and diabe-155, ch. des Boveresses
tes. There are several isoforms of PI3K linked to differentCH-1066 Epalinges/Lausanne
receptor systems and with apparently discrete functionsSwitzerland
in cells and in the organism (reviewed in Vanhaese-
broeck et al., 2001). These include the p110, , and 
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isoforms that play a role in tyrosine-kinase-signaling
pathways. In contrast, p110 transmits PI3K signalsAravind, L., and Koonin, E.V. (2000). Curr. Biol. 10, R132–R134.
downstream of G protein-coupled receptors (GPCRs).Ballinger, C.A., Connell, P., Wu, Y., Hu, Z., Thompson, L.J., Yin, L.Y.,
p110 is highly expressed in white blood cells and theand Patterson, C. (1999). Mol. Cell. Biol. 19, 4535–4545.
phenotype of the p110 KO mouse, published by three
Barral, J.M., Hutagalung, A.H., Brinker, A., Hartl, F.U., and Epstein,
independent groups in Science a few years ago (DekkerH.F. (2002). Science 295, 669–671.
and Segal, 2000), seemed straightforward at first. These
Hoppe, T., Cassata, G., Barral, J.M., Springer, W., Hutagalung, A.H.,
p110KO mice were apparently healthy but had a damp-Epstein, H.F., and Baumeister, R. (2004). 118, this issue, 337–349.
ened immune response when challenged with inflamma-
Hutagalung, A.H., Landsverk, M.L., Price, M.G., Epstein, H.F., Barral,
tory stimuli. This phenotype was due to decreased in-J.M., Brinker, A., and Hartl, F.U. (2002). J. Cell Sci. 115, 3983–3990.
flammatory migration of macrophages and reduced
Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Naka- production of inflammatory substances by neutrophils.
yama, K.I., and Takahashi, R. (2002). Mol. Cell 10, 55–67.
These studies caused quite a stir and put p110 on the
Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H.D., Mayer, T.U., and top of the wish list of many pharmaceutical companies
Jentsch, S. (1999). Cell 96, 635–644.
in their quest for new anti-inflammatory drug targets.
Mahoney, J.A., Odin, J.A., White, S.M., Shaffer, D., Koff, A., Casciola- This enthusiasm was greatly tempered by a follow-up
Rosen, L., and Rosen, A. (2002). Biochem. J. 361, 587–595. report that the p110 KO mice developed colon cancer
Nikolay, R., Wiederkehr, T., Rist, W., Kramer, G., Mayer, M.P., and (Sasaki et al., 2000). Given that inflammation often re-
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would certainly be an undesirable side effect of p110
Pickart, C.M. (2004). Cell 116, 181–190. inhibitors. However, independently created p110 KO
mouse lines did not develop cancer (Barbier et al., 2001).
The exact reason for the isolated case of a cancer phe-
notype is still not clear (Sasaki et al., 2003) but is possibly
Gene Targeting: Attention to Detail related to mutations acquired in the ES cells during
culture and gene targeting. This finding put the minds of
p110 drug developers at rest, but only for a little while.
Further alarm bells went off when it became clear
that the p110 KO mice, apart from an immunological
When it comes to silencing genes in mice, not all ap- phenotype, also had a cardiac defect, namely increased
proaches are equal. An example published in this issue contractility (Crackower et al., 2002). PI3K action has
of Cell (Patrucco et al., 2004) suggests that caution been implicated in cardiac function and several GPCR-
should be used when validating potential drug targets signaling pathways, including those triggered by adren-
ergic receptors, have important functions in the heartby genetic disruption
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Figure 1. PI3K Signaling in the Heart
The interaction of p110 with PDE3B regu-
lates cAMP levels in the heart to control con-
tractility, independent of the kinase activity
of p110. It is not clear whether this action of
p110 requires GPCR stimulation or whether
the interaction of p110 with PDE3B is direct.
Kinase-dependent activities of p110 include
the generation of PIP3 (leading to the activa-
tion of the protein kinase Akt/PKB) and the
activation of Erk and p38 MAPK family mem-
bers. These pathways can also be switched
on by other PI3K isoforms (such as p110,
which signals downstream of growth factor
receptors which are often tyrosine kinases)
or by deletion of the PIP3 phosphatase PTEN.
Although the control of heart contractility by
p110 appears to be mainly regulated by its
kinase-independent functions on cAMP, PIP3
also regulates a negative feedback loop that
facilitates the internalization of GPCR recep-
tors, such as the -adrenergic receptors. For
a review, see Prasad et al. (2003). Figure pre-
pared by Sarah Barnsley.
(Figure 1; reviewed in Prasad et al., 2003). The inappro- activity and therefore increased levels of cAMP. Taken
together, these data suggest that p110 may have, inpriate contractility in the p110 KO mouse correlated
addition to its catalytic function, a previously unrecog-with an increase in the baseline concentration levels of
nized scaffolding role in the assembly of protein com-the second messenger cAMP in cardiomyocytes (Crack-
plexes regulating cAMP metabolism. Control of signal-ower et al., 2002). cAMP activates protein kinase A (PKA)
ing by protein:protein interactions and scaffolding is awhich in turn phosphorylates several substrates in the
theme that has been poorly investigated by mouse geneheart, including phospholamban, troponin I, and the L-type
targeting and is more actively being explored within theCa2 channel, leading to enhanced contractility. The loss
realm of large-scale yeast 2-hybrid screens, advancedof p110 expression in the KO mouse also results in
proteomics, and systems biology studies.massive cardiac necrosis under stress conditions such
Where does all this leave p110 as a drug target?as experimental transverse aortic constriction (TAC)
Mutating the ATP binding site of an individual PI3K iso-which mimics chronic pressure overload of the heart
form abolishes catalytic function while still allowing ki-(Patrucco et al., 2004). These observations would under-
nase-independent phenomena (as the PDE3B arm ofstandably make any drug company wary of pursuing
the pathway appears to be). Such manipulation mimicsthis gene as an anti-inflammatory drug target, no matter
a small molecule inhibitor far more accurately than doeshow potentially valuable.
a gene knockout, and as long as such a mutated proteinHowever, in the latest twist to the story, Hirsch and
is not overexpressed, it is unlikely to have dominant-coworkers report in this issue (Patrucco et al., 2004) that
negative effects on other PI3K family members. Indeed,mice in which p110 is inactivated by introducing a
kinase inhibitors do not induce the loss of expressionkinase-dead allele into the p110 locus retain their im-
of their target proteins but most often compete withmunological defects but no longer show the increased
cellular ATP for binding to the target kinase. A drawbackcontractility and do not develop cardiac tissue damage
of the strategy applied by Hirsch et al. (Patrucco et al.,upon pressure overload. Basic heart physiology under
2004) is that the p110 gene was inactivated early in
nonstressed conditions appears to be unaffected in the
development, which gives the organism ample time for
p110 KI mice. The activation of Akt/PKB, Erk1/2, and adaptation. Strategies of inducible gene knockin have
p38 MAPK family members by TAC was similarly blunted been developed, and will certainly be exploited in this
in the p110 KO and p110 KI hearts. This indicated context in the future. It also remains to be seen whether
that other signaling pathways most likely underlie the acute inhibition of p110 using pharmacological tools
distinct phenotypes induced by the different inactivation will have the same impact as the knockin mutation in
strategies of p110. the mouse. Intriguingly, Patrucco et al. (2004) also pre-
Attention now returned to cAMP—would it be differ- sented evidence that loss of p110 kinase activity in the
ently affected by the two targeting strategies? Indeed, KI mice leads to decreased hypertrophy and reduced
unlike the p110 KO mice, the p110 KI mice did not fibrosis in the heart under stress conditions (Figure 1).
have elevated levels of cAMP in the heart. How then Small molecule inhibitors of p110 might therefore be
does this increase in cAMP in the heart of p110 KO potentially useful not only as anti-inflammatories, but
mice come about? Apparently, p110 forms a complex also in (pre)pathological conditions of heart hypertrophy
with phosphodiesterase 3B (PDE3B), a key molecule in and fibrosis. And of course, mouse models, while help-
the degradation of cAMP (Figure 1). The expression level ing to validate a drug target, are by no means a substi-
of PDE3B in the heart was not altered in p110 KO or tute for the real world of human pharmacology. For this
KI mice but its activity was found to be reduced only in reason, it will be interesting to find out how the p110
drugs will perform in the clinic!the p110KO. KO of p110 thus leads to reduced PDE3B
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